Association of metformin administration after septic shock with short-term and long-term survival in septic shock patients with diabetes
Authors' conclusion
In septic shock patients with type 2 diabetes mellitus, metformin administration within 48 h was associated with lower 90-day and 365-day mortality.
Study context
- Population
- Adult septic shock patients with type 2 DM, sepsis registry, October 2016 to June 2022
- Participants
- 320 patients
- Exposure
- Metformin vs No metformin
- Outcome
- 90-day mortality and 365-day mortality
Methodological detailsprospectively collected sepsis registry, multivariable Cox proportional hazards model
- Prospectively collected sepsis registry
- Multivariable Cox proportional hazards model
Main finding
As reported in the abstract
90-day and 365-day mortality
Metformin vs No metforminAdjusted hazard ratio (95% CI)P value
90-day mortality; unadjusted P < 0.001
0.371(0.153–0.900)
P = 0.028365-day mortality; unadjusted P = 0.001
0.453(0.219–0.937)
P = 0.033Observational data: associations, not effects.
Further findings
In-hospital mortality
P = 0.002
Metformin within 72 h: 90-day and 365-day mortality
| aHR (95% CI) | P value | ||
|---|---|---|---|
| Metformin within 72 h90-day mortality | 0.433 (0.235–0.797) | P = 0.007 | |
| Metformin within 72 h365-day mortality | 0.450 (0.264–0.767) | P = 0.003 | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Original publication
Association of metformin administration after septic shock with short-term and long-term survival in septic shock patients with diabetes. Ann Intensive Care. Published 21 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →